Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

What can speech tell us about pain?

  • Posted on 26 June, 2025
    Pain is deeply personal, yet universally expressed through speech. But what if speech isn’t just a way we describe pain,...
    Read more

    Understanding speech and language in KIF1A-associated neurological disorder

    • Posted on 17 June, 2025
      A new study published in the European Journal of Human Genetics provides the first systematic analysis of speech and language...
      Read more

      Redenlab contributes to position paper on advancing digital healthtechnologies for frontotemporal degeneration

      • Posted on 15 May, 2025
        MEDIA RELEASE MELBOURNE, VIC – A major collaborative paper published in Alzheimer’s & Dementia introduces a critical roadmap for the...
        Read more